Bioventus (BVS) Operating Expenses (2020 - 2026)

Bioventus (BVS) has 7 years of Operating Expenses data on file, last reported at $81.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 6.19% year-over-year to $81.2 million; the trailing twelve-month figure through Mar 2026 stood at $330.9 million (down 6.22% YoY), and the FY2025 full-year result was $336.4 million, down 8.64% from the prior year.
• Operating Expenses for Q1 2026 stood at $81.2 million, down from $85.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $100.9 million in Q2 2024 and bottomed at $72.8 million in Q3 2023.
• The 5-year median for Operating Expenses is $84.1 million (2022), against an average of $85.1 million.
• The widest annual swing landed in 2022, when Operating Expenses surged 162.76%; it then retreated 18.69% in 2023.
• A 5-year view of Operating Expenses shows it stood at $88.0 million in 2022, then fell by 7.33% to $81.5 million in 2023, then increased by 10.48% to $90.1 million in 2024, then fell by 4.8% to $85.8 million in 2025, then slipped by 5.27% to $81.2 million in 2026.
• The last three Operating Expenses figures came in at $81.2 million (Q1 2026), $85.8 million (Q4 2025), and $81.6 million (Q3 2025), per Business Quant data.

Peer Comparison